NASDAQ:ICU SeaStar Medical Q2 2024 Earnings Report $2.95 +0.01 (+0.34%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast SeaStar Medical EPS ResultsActual EPS-$10.30Consensus EPS -$14.10Beat/MissBeat by +$3.80One Year Ago EPSN/ASeaStar Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASeaStar Medical Announcement DetailsQuarterQ2 2024Date8/13/2024TimeAfter Market ClosesConference Call DateTuesday, August 13, 2024Conference Call Time7:00AM ETUpcoming EarningsSeaStar Medical's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) SeaStar Medical Earnings HeadlinesContrasting Aclarion (NASDAQ:ACON) & SeaStar Medical (NASDAQ:ICU)June 5 at 4:25 AM | americanbankingnews.comICU: YoY revenue increases 69%May 18, 2026 | msn.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 8 at 1:00 AM | Porter & Company (Ad)SeaStar Medical Holding Corp (ICU) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 14, 2026 | finance.yahoo.comSeastar Medical targets about $2M 2026 QUELIMMUNE revenue while aiming to finish NEUTRALIZE-AKI enrollment by end of 2026May 13, 2026 | seekingalpha.comSeaStar Medical (ICU) Q1 2026 Earnings TranscriptMay 13, 2026 | fool.comSee More SeaStar Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SeaStar Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SeaStar Medical and other key companies, straight to your email. Email Address About SeaStar MedicalSeaStar Medical (NASDAQ:ICU), Inc. (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies. The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR. TriGUARD 3 features an advanced frame and filter design that conforms to varying patient anatomies, enabling physicians to position the device safely and effectively without obstructing critical arterial access routes. SeaStar Medical continues to invest in clinical trials and registry studies to demonstrate the safety and performance of its technology and to support regulatory clearances in North America, Europe and other key markets. Headquartered in Kansas City, Missouri, SeaStar Medical serves a global customer base through direct sales and distribution partnerships in Europe and parts of Asia Pacific, in addition to its U.S. operations. The company collaborates with interventional cardiologists, cardiac surgeons and research institutions to refine device design and expand indications. Its leadership team brings extensive experience from leading cardiovascular and medical device firms, guiding SeaStar Medical through product development, regulatory interactions and market introduction efforts to address the growing demand for neuroprotection in structural heart care.View SeaStar Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?Docusign: Another Beat, Another Selloff—Why the Analysts Are WrongA Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?Petco Faces Tough Competition, But Momentum Is BuildingIREN's 800MW Bet Flips the AI Power Switch Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
